Abstract:Linagliptin is a new DPP‐4 inhibitor licensed for use as monotherapy or in combination in type 2 diabetes. Our New products review presents the clinical data relating to its efficacy and adverse events and considers its place in treatment, particularly in patients with renal impairment
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.